Drug intelligence / Profile preview

Intragel

Development stage: Phase 3
Lead developer: IBSA
Administration: Intra-articular Injection

Overview

Intragel is a hyaluronic acid (HA) formulation designed for viscosupplementation, primarily used in the treatment of osteoarthritis. It is administered via intra-articular injection to alleviate pain and enhance joint function. The formulation contains 16mg of hyaluronic acid per 2cc, with an average molecular weight ranging from 800 to 1200 kiloDaltons. It works by restoring the elastoviscosity of the synovial fluid, thereby improving joint lubrication, shock absorption, and providing anti-inflammatory and analgesic effects. Intragel is developed and manufactured by IBSA.

Brand names: IntragelSinovialYaral
Other names: sodium hyaluronatehyaluronic acid

Targets

ICAM1 (Intercellular Adhesion Molecule 1)RHAMM (Hyaluronan-mediated motility receptor)CD44 (CD44 antigen)

Beyond the preview

Go deeper on Intragel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intragel.

Explore the full profile